title: Ipratropium bromide nasal spray 0.03% and beclomethasone nasal spray alone and in combination for the treatment of rhinorrhea in perennial rhinitis.
abstract: BACKGROUND
  Perennial rhinitis is a common condition that affects up to 10% to 20% of the population. Multiple agents are frequently administered since no single agent provides complete relief. Studies assessing the benefit/risk of combined therapy are important especially for newly approved agents such as ipratropium bromide nasal spray 0.03%, a topical anticholinergic agent, approved specifically for the treatment of rhinorrhea in allergic and non-allergic perennial rhinitis.
  
  
  OBJECTIVE
  To compare the efficacy and safety of the combined use of ipratropium bromide nasal spray 0.03% (42 microg per nostril tid) and beclomethasone dipropionate nasal spray (84 microg per nostril bid) against that of either active agent alone for the treatment of rhinorrhea.
  
  
  METHODS
  Multicenter, 6-week, double-blind, randomized active- and placebo-controlled, parallel trial.
  
  
  METHODS
  Allergist and general practitioner clinical practices.
  
  
  METHODS
  Five hundred thirty-three patients with perennial rhinitis (279 allergic and 274 non-allergic), 8 to 75 years of age, who had at least a mild degree of severity of rhinorrhea for a minimum of 2 hours per day during the 1 week screening period as well as congestion or sneezing also of at least mild severity.
  
  
  METHODS
  Either (1) ipratropium bromide nasal spray 0.03% (42 microg per nostril tid) plus beclomethasone dipropionate nasal spray (84 microg per nostril bid), (2) ipratropium bromide nasal spray 0.03% (42 microg per nostril tid) alone, (3) beclomethasone dipropionate nasal spray (84 microg per nostril bid) alone, or (4) vehicle [matching placebo nasal spray for the ipratropium bromide (2 sprays per nostril tid)] or beclomethasone dipropionate (2 sprays per nostril bid).
  
  
  METHODS
  Severity and duration of rhinorrhea, and patient and physician global assessment of control of rhinorrhea.
  
  
  RESULTS
  Ipratropium bromide nasal spray plus beclomethasone nasal spray was more effective than either active agent alone or vehicle in reducing the average severity and duration of rhinorrhea during 4 weeks of treatment. The advantage of ipratropium bromide plus beclomethasone nasal spray was evident by the first day of combined treatment and continued throughout the 2-week treatment period. Ipratropium bromide nasal spray had a faster onset of action during the first week of treatment and reduced the duration of rhinorrhea more than beclomethasone. Beclomethasone nasal spray was more effective in reducing the severity of congestion and sneezing than ipratropium. In patients who had not responded well to a nasal steroid prior to participation in the study based on a questionnaire administered at screening, ipratropium bromide was as effective in the steroid non-responders as steroid responders, whereas beclomethasone was more effective in steroid responders. Combined active therapy was well tolerated with no increase in adverse events over that seen previously with ipratropium bromide or beclomethasone nasal spray alone.
  
  
  CONCLUSIONS
  The combined use of ipratropium bromide nasal spray with beclomethasone dipropionate nasal spray is more effective than either active agent for the treatment of rhinorrhea, and does not result in a potentiation of adverse drug reactions. Ipratropium bromide nasal spray 0.03% alone should be considered in patients for whom rhinorrhea is the primary symptom, and its use in combination with a nasal steroid should be considered in patients where rhinorrhea is one of the predominant symptoms, or in patients with rhinorrhea not fully responsive to other therapy.
authors.affiliation: Department of Medicine, University of Missouri Kansas City, USA.
authors.forename: R
authors.initials: R
authors.lastname: Dockhorn
authors.forename: D
authors.initials: D
authors.lastname: Aaronson
authors.forename: E
authors.initials: E
authors.lastname: Bronsky
authors.forename: P
authors.initials: P
authors.lastname: Chervinsky
authors.forename: R
authors.initials: R
authors.lastname: Cohen
authors.forename: R
authors.initials: R
authors.lastname: Ehtessabian
authors.forename: A
authors.initials: A
authors.lastname: Finn
authors.forename: J
authors.initials: J
authors.lastname: Grossman
authors.forename: W
authors.initials: W
authors.lastname: Howland
authors.forename: H
authors.initials: H
authors.lastname: Kaiser
authors.forename: D
authors.initials: D
authors.lastname: Pearlman
authors.forename: J
authors.initials: J
authors.lastname: Sublett
authors.forename: P
authors.initials: P
authors.lastname: Ratner
authors.forename: G
authors.initials: G
authors.lastname: Settipane
authors.forename: T
authors.initials: T
authors.lastname: Sim
authors.forename: W
authors.initials: W
authors.lastname: Storms
authors.forename: R
authors.initials: R
authors.lastname: Webb
authors.forename: K
authors.initials: K
authors.lastname: Drda
authors.forename: C
authors.initials: C
authors.lastname: Wood
mesh_terms: D000280:Administration, Inhalation; D000293:Adolescent; D000328:Adult; D000368:Aged; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D001507:Beclomethasone / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001993:Bronchodilator Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D002648:Child; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D009241:Ipratropium / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011788:Quality of Life; D012220:Rhinitis / Q000188:drug therapy*; D012221:Rhinitis, Allergic, Perennial / Q000188:drug therapy*
chemical_list: D018927:Anti-Asthmatic Agents; D001993:Bronchodilator Agents; D009241:Ipratropium; D001507:Beclomethasone